| Author | Chaves, Janaina Braga | |
| Author | Moraes, Bianca Portugal Tavares de | |
| Author | Ferrarini, Stela Regina | |
| Author | Fonseca, Francisco Noé da | |
| Author | Silva, Adriana Ribeiro | |
| Author | Albuquerque, Cassiano Felippe Gonçalves de | |
| Access date | 2022-12-04T15:03:58Z | |
| Available date | 2022-12-04T15:03:58Z | |
| Document date | 2022 | |
| Citation | CHAVES, Janaina Braga et al. Potential of nanoformulations in malaria treatment. Frontiers in Pharmacology, v. 13, 999300, p. 1 - 17, Oct. 2022. | en_US |
| ISSN | 1663-9812 | en_US |
| URI | https://www.arca.fiocruz.br/handle/icict/55888 | |
| Language | eng | en_US |
| Publisher | Frontiers Media | en_US |
| Rights | open access | |
| Subject in Portuguese | Malária | en_US |
| Subject in Portuguese | Tratamento | en_US |
| Subject in Portuguese | Estudo pré-clínico | en_US |
| Subject in Portuguese | Nanotecnologia | en_US |
| Subject in Portuguese | Doenças infecciosas | en_US |
| Title | Potential of nanoformulations in malaria treatment | en_US |
| Type | Article | |
| DOI | 10.3389/fphar.2022.999300 | |
| Abstract | Malaria is caused by the protozoan Plasmodium sp and affects millions of
people worldwide. Its clinical form ranges from asymptomatic to potentially
fatal and severe. Current treatments include single drugs such as chloroquine,
lumefantrine, primaquine, or in combination with artemisinin or its derivatives.
Resistance to antimalarial drugs has increased; therefore, there is an urgent
need to diversify therapeutic approaches. The disease cycle is influenced by
biological, social, and anthropological factors. This longevity and complexity
contributes to the records of drug resistance, where further studies and
proposals for new therapeutic formulations are needed for successful
treatment of malaria. Nanotechnology is promising for drug development.
Preclinical formulations with antimalarial agents have shown positive results,
but only a few have progressed to clinical phase. Therefore, studies focusing on
the development and evaluation of antimalarial formulations should be
encouraged because of their enormous therapeutic potential. | en_US |
| Affilliation | Universidade Federal do Estado do Rio de Janeiro. Departamento de Bioquímica. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil | en_US |
| Affilliation | Universidade Federal do Estado do Rio de Janeiro. Departamento de Bioquímica. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil | en_US |
| Affilliation | Universidade Federal do Estado do Mato Grosso. Laboratório de Nanotecnologia Farmacêutica. Campus SInop. UFMT. Cuiabá, MT, Brasil. | en_US |
| Affilliation | Empresa Brasileira de Pesquisa Agropecuária, Parque Estação Biológica—PqEB, EMBRAPA, Brasília, DF, Brasil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil. | en_US |
| Affilliation | Universidade Federal do Estado do Rio de Janeiro. Departamento de Bioquímica. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.. | en_US |
| Subject | Malaria | en_US |
| Subject | Treatment | en_US |
| Subject | Pre-clinical study | en_US |
| Subject | Nanotechnology | en_US |
| Subject | Infectious diseases | en_US |
| xmlui.metadata.dc.subject.ods | 03 Saúde e Bem-Estar | |
